Century Therapeutics (NasdaqGS:IPSC) FY Conference Transcript

Century Therapeutics Conference Call Summary Company Overview - Company: Century Therapeutics (NasdaqGS: IPSC) - Focus: Development of iPSC-derived cell therapies with a strong emphasis on immune evasion technology [2][3] Key Programs CNTY-813 (Type 1 Diabetes Program) - Description: iPSC-derived beta islet cell replacement therapy with advanced immune evasion technology (AlloVation 5.0) - Current Status: In IND-enabling studies, expected IND submission by late 2026 - Potential Impact: Aims to provide a functional cure for Type 1 diabetes, addressing a significant unmet medical need for approximately 10 million patients globally [3][25] CNTY-308 (Alpha Beta T Cell Program) - Description: iPSC-derived T cell therapy targeting CD19 for B-cell-mediated autoimmune diseases - Current Status: Targeting clinical push within the year, leveraging the same AlloVation 5.0 technology - Differentiation: Claims to offer comparable efficacy to autologous T cells without the need for lymphodepletion [4][46] Technology and Innovation - iPSC Advantages: Unlimited scalability and ability to differentiate into any adult cell type, making them ideal for cell-based therapies [11][12] - AlloVation 5.0: Advanced immune evasion technology that includes: - Removal of Class I and Class II HLAs to prevent T cell response - Insertion of a universal pan-NK inhibitory ligand (CD300a TASR) to mitigate NK cell response - IgG-degrading protease to protect against antibody-mediated rejection [15][17][21] Clinical Development and Regulatory Path - IND Submission Timeline: On track for submission in late 2026, with positive feedback from the FDA regarding the evidence package [32][37] - Clinical Trial Goals: Focus on safety, engraftment, and functionality of cells, with a target to reduce or eliminate chronic immunosuppression [34][39] Market Opportunity - Target Population: Initial focus on severe Type 1 diabetes patients with multiple hypoglycemic events, estimated at 60,000 in the U.S. alone, with potential expansion to 200,000-250,000 patients [43][45] - Long-term Vision: Aiming for commercialization in the early 2030s, contingent on successful clinical data and regulatory approvals [38] Financial Position - Cash Runway: Recent capital raise extends cash runway to Q1 2029, covering key clinical milestones [54] Additional Insights - Preclinical Data: Extensive data supporting the efficacy of CNTY-813 and CNTY-308, including successful animal model results demonstrating normoglycemia and persistence of T cells [19][50] - Competitive Landscape: Acknowledgment of the competitive nature of the cell therapy space, with a commitment to high benchmarks for clinical outcomes [52] This summary encapsulates the critical elements discussed during the conference call, highlighting Century Therapeutics' strategic focus, innovative technologies, and market potential in the field of cell therapies.